Ascenta Capital

Ascenta Capital is a venture capital firm founded in 2023, focusing on multi-medicine development-stage biotechnology companies. The firm leads or co-leads investments in biotech companies at the early stages of human trials, aiming to support the translation of scientific foundations into meaningful medicines for patients. Ascenta's team comprises professionals with deep biotech operating and investment expertise, collectively having played critical roles in more than 30 approved medicines during their careers.

The firm's investment strategy is intentionally selective, focusing on a small number of exceptional biotechs to provide concentrated support in clinical, regulatory, manufacturing, scientific, and capital strategy. Ascenta's portfolio includes companies such as ADARx Pharmaceuticals, Iambic Therapeutics, Odyssey Therapeutics, Cardurion Pharma, OrsoBio, and Alpha9 Oncology. These companies are collectively active in 14 clinical trials and have more than 40 pipeline programs.

In October 2025, Ascenta Capital announced the final close of its inaugural $325 million fund, with investors spanning family and multi-family offices, endowments & foundations, and high net-worth individuals. The firm has deployed over $100 million of capital into its portfolio companies, reflecting its commitment to supporting innovative biotech ventures at critical stages of development.